Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function by Fu, Maofu et al.
MOLECULAR AND CELLULAR BIOLOGY, May 2002, p. 3373–3388 Vol. 22, No. 10
0270-7306/02/$04.000 DOI: 10.1128/MCB.22.10.3373–3388.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Androgen Receptor Acetylation Governs trans Activation and
MEKK1-Induced Apoptosis without Affecting In Vitro
Sumoylation and trans-Repression Function
Maofu Fu,1 Chenguang Wang,1 Jian Wang,1 Xueping Zhang,1 Toshiyuki Sakamaki,1 Y. G. Yeung,1
Chawnshang Chang,2 Torsten Hopp,3 Suzanne A. W. Fuqua,3 Ellis Jaffray,4 Ron T. Hay,4
Jorma J. Palvimo,5 Olli A. Jänne,5 and Richard G. Pestell1*
Department of Developmental and Molecular Biology and Medicine, The Albert Einstein Comprehensive Cancer Center, Albert
Einstein College of Medicine, Bronx, New York 104611; George Whipple Laboratory for Cancer Research, Departments of Urology,
Pathology, Radiation Oncology, Biochemistry, and Toxicology, and The Cancer Center, University of Rochester, Rochester,
New York 146422; Baylor College of Medicine, Houston, Texas 770303; School of Biology, University of St. Andrews,
The North Haugh, St. Andrews KY16 9ST, Scotland4; and Biomedicum Helsinki, Institute of Biomedicine
and Department of Clinical Chemistry, FIN-00014 University of Helsinki, Finland5
Received 16 July 2001/Returned for modification 10 September 2001/Accepted 14 February 2002
The androgen receptor (AR) is a nuclear hormone receptor superfamily member that conveys both trans
repression and ligand-dependent trans-activation function. Activation of the AR by dihydrotestosterone (DHT)
regulates diverse physiological functions including secondary sexual differentiation in the male and the
induction of apoptosis by the JNK kinase, MEKK1. The AR is posttranslationally modified on lysine residues
by acetylation and sumoylation. The histone acetylases p300 and P/CAF directly acetylate the AR in vitro at a
conserved KLKK motif. To determine the functional properties governed by AR acetylation, point mutations
of the KLKK motif that abrogated acetylation were engineered and examined in vitro and in vivo. The AR
acetylation site point mutants showed wild-type trans repression of NF-B, AP-1, and Sp1 activity; wild-type
sumoylation in vitro; wild-type ligand binding; and ligand-induced conformational changes. However, acety-
lation-deficient AR mutants were selectively defective in DHT-induced trans activation of androgen-responsive
reporter genes and coactivation by SRC1, Ubc9, TIP60, and p300. The AR acetylation site mutant showed
10-fold increased binding of the N-CoR corepressor compared with the AR wild type in the presence of ligand.
Furthermore, histone deacetylase 1 (HDAC1) bound the AR both in vivo and in cultured cells and HDAC1
binding to the AR was disengaged in a DHT-dependent manner. MEKK1 induced AR-dependent apoptosis in
prostate cancer cells. The AR acetylation mutant was defective in MEKK1-induced apoptosis, suggesting that
the conserved AR acetylation site contributes to a pathway governing prostate cancer cellular survival. As AR
lysine residue mutations that abrogate acetylation correlate with enhanced binding of the N-CoR repressor in
cultured cells, the conserved AR motif may directly or indirectly regulate ligand-dependent corepressor
disengagement and, thereby, ligand-dependent trans activation.
Steroid receptors, including the androgen receptor (AR),
are members of the nuclear receptor (NR) superfamily which
generally function as ligand-dependent transcriptional regula-
tors (9, 31, 84). The AR is expressed in a variety of cell types
and plays an important role in development, male sexual dif-
ferentiation, and prostate cellular proliferation. The functional
domains of the AR (termed A to F) are conserved with other
members of the classical receptor subclass. The C-terminal
region of the AR, including the hinge region and ligand-bind-
ing domain (LBD), is responsible for ligand binding and
dimerization. The well-conserved DNA binding domain con-
sists of 68 amino acids with two zinc finger structures. The
N-terminal region contributes to transcriptional activation
through its activation function 1 (AF-1) (5). In contrast to
several other hormone-regulated NRs, the AR lacks an intrin-
sic AF-2 function in the LBD. The LBD, which consists of 12
 helices projecting away from the hormone-binding pocket in
the absence of ligand, undergoes substantial conformational
changes in the presence of ligand. The folding of the most
carboxyl-terminal helix 12 over the ligand-binding pocket in
turn creates new structural surfaces that bind coactivators re-
quired for efficient transactivation.
Several AR coactivators have been identified, including the
p160 proteins, the p300/CREB-binding protein (CBP) family,
Ubc9, ARA70, ARA55, and TIP60 (1, 5, 15, 68, 92). The
efficient recruitment of coactivators to the AR involves an
association between both the AR amino terminus and the LBD
(5, 34). The coactivator proteins regulate gene expression
through several distinct mechanisms. CBP and the related
functional homologue p300 (CBP/p300) convey a bridging
function between the DNA-bound transcription factor and the
basal apparatus and provide a scaffold to assemble high-mo-
lecular-weight enhanceosomes (reviewed in reference 26). In
addition, the cointegrator proteins p300/CBP share the capac-
ity to acetylate histones, which correlates, under certain cir-
cumstances, with their transcriptional coactivator function (54,
87). Acetylation facilitates binding of transcription factors to
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specific target DNA sequences by destabilizing nucleosomes
bound to the promoter region of a target gene (45, 61). Fur-
thermore, cointegrators may directly acetylate nonhistone pro-
teins, including transcription factor, to regulate their activity
(reviewed in references 81 and 87). Acetylation of the tumor
suppressor p53 (51), the transcription factor erythroid Krup-
pel-like factor (95), and the erythroid cell differentiation factor
GATA-1 (33) enhanced their transactivation functions. More
recently nuclear hormone receptors (NHR) and NR coacti-
vators were shown to serve as targets of acetylation. Direct
acetylation of the nuclear receptor coactivator ACTR (18)
or estrogen receptor  (86) contributed to ligand-dependent
transcriptional attenuation. The AR is acetylated in vitro and
in cultured cells at a conserved KLKK motif (23). Mutation of
the AR KLKK motif abrogated acetylation of the AR in cul-
tured cells and reduced ligand-dependent activity (23). How-
ever, the role of the AR acetylation site in regulating the other
diverse functions of the AR is not known.
The AR conveys both trans activation and trans-repression
function. The mechanism by which the AR represses expres-
sion of other transcription factors is a relatively poorly under-
stood process. The AR inhibits activity of both c-Jun and c-Fos
through mechanisms that may involve direct protein-protein
interaction or competition for limiting coactivators (62, 76).
Several genes downregulated by androgens contain NF-B
binding sites in their promoters, and components of tumor
necrosis factor alpha (TNF-)-dependent antiproliferation re-
quired the AR, suggesting an important function for AR–
NF-B cross talk in prostate cancer cells. The AR binds to
RelA and attenuates RelA-mediated trans activation at an
NF-B site, consistent with a role for direct physical binding of
NF-B proteins in AR trans repression (62).
The activity of several NHR, such as the thyroid hormone
receptor and the retinoic acid receptor, is actively repressed in
the absence of ligand by binding to the corepressor protein
N-CoR or SMRT. N-CoR and SMRT are largely modular
proteins that interact with NHR through their C termini. The
N-terminal repression domain interacts with histone deacety-
lase (HDAC) complexes. Upon recognition of their substrates,
acetylated lysine residues of histone, HDACs remove acetyl
groups from lysine residues, resulting in a more compact chro-
matin structure, decreasing the accessibility of the chromatin
for transcription factors. In the case of the Rev-erb NHR
superfamily member, N-CoR contacts both the NHR and the
basal transcription apparatus. As some components of the
basal apparatus are acetylated, it has been proposed that
deacetylation may also decrease transcriptional activity. The
mechanisms responsible for repressing the activity of the AR
are not well understood. The cell cycle regulatory protein cy-
clin D1 and an intracellular transducer of transforming growth
factor  signaling, Smad3, are reported to inhibit the activity of
the ligand-treated AR (29, 44, 73). Smad3 repression of other
NRs involves, at least in part, hormone-sensitive interactions
with the corepressors N-CoR, SMRT, and Alien, which bind to
the SIN3 proteins and recruit HDAC activity (17, 43). The
finding that coactivator and corepressor surfaces of NHR over-
lap substantially (32, 66) is compatible with a dynamic model in
which enzymatic modifications of the NR coordinate sequen-
tial disengagement of corepressors followed by coactivator
binding (56). Whether such processes regulate AR activity
remains to be determined.
In addition to responding to ligands, the AR is modified by
kinase signaling pathways. The mitogen-activated protein ki-
nase (MAPK) kinase kinase 1 (MEKK1) leads to activation of
MKK4 and JNK (46). Constitutively active alleles of MEKK1
can induce cellular apoptosis (25, 89). Activity of the AR is
enhanced by constitutively active MEKK1 expression that in-
duces cellular apoptosis in an AR-dependent manner (2). The
AR is also posttranslationally modified by sumoylation. The
modification of proteins by SUMO-1 (sumoylation) is a revers-
ible, conserved, enzymatic event targeted to a lysine within the
motif KXE (where  represents a large hydrophobic amino
acid and X represents any amino acid) within the protein
target. Conjugation of the small ubiquitin-like modifier
SUMO-1/SMT3C/Sentrin-1 to cellular substrates involves an
E1-like enzyme known as SAE1/SAE2. SUMO-1 is transferred
from the E1 to a cysteine within the SUMO-specific residue
E2-conjugating enzyme (Ubc9). Ubc9 then catalyzes an
isopeptide bond between SUMO-1 and the ε-amino group of
lysine in the target protein. A proportion of the AR is sumoy-
lated in cultured cells (70), and like sumoylation of c-Jun (57),
sumoylation of the AR attenuates AR transactivation function
(70). The specificity for the target protein of sumoylation is
thought to reside with Ubc9 itself. Ubc9 binds the AR within
the hinge region (68) that includes the site of direct acetyla-
tion, raising the possibility that AR acetylation may in turn
affect modification by SUMO-1 and, thereby, transactivation.
The role of AR acetylation in AR trans repression and trans
activation for specific target genes and the molecular mecha-
nisms by which the AR acetylation site regulates transcrip-
tional coregulator complex recruitment are unknown. Further-
more, the functional consequence of the AR acetylation site on
cellular phenotype is unknown. As similar types of questions
either remain to be addressed or are controversial with other
transcription factors that are directly acetylated, such as p53
(72), it is likely that analysis of the AR acetylation site may
provide insight into the function of other acetylated transcrip-
tion factors. In this study, we investigated the functional sig-
nificance of the conserved lysine residue motif within the AR
hinge region that was previously shown to serve as a substrate
for acetylation by the histone acetyltransferase (HAT) p300
and P/CAF (23). The AR mutations at the acetylation site
maintained trans-repression function, bound ligands with wild-
type affinity, were sumoylated, and conveyed 80 to 90% of the
basal activity of the AR wild type (ARwt). The dihydrotestos-
terone (DHT)-induced activity of the androgen-responsive re-
porter genes, prostate-specific antigen (PSA), mouse mam-
mary tumor virus (MMTV), and an androgen-responsive
element (ARE) reporter was abrogated. Coactivation by
SRC1, p300, Ubc9, and TIP60 was abolished. Binding of the
AR mutant to the corepressor N-CoR in the presence of ligand
was increased, suggesting a critical role for these lysine resi-
dues in ligand-dependent recruitment of N-CoR. Prostate can-
cer cell lines stably expressing either ARwt or AR acetylation
mutants demonstrated a resistance of the AR acetylation site
mutant lines to several apoptosis-inducing agents. Mutation of
the AR acetylation site abrogated MEKK1-induced apoptosis.
These studies indicate that the conserved AR lysine residues,
which are acetylated in vitro and in cultured cells, play a role in
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coordinating a subset of AR functions, including corepressor
disengagement, ligand-induced transactivation, and cellular
apoptosis.
MATERIALS AND METHODS
Reporter genes and expression vectors. The expression vector pCMVHA-p300
(4) and the AR-regulated reporter genes PSA-LUC, a 600-bp fragment of the
PSA promoter with an additional 2.4-kb enhancer sequence cloned upstream of
luciferase (PSA P/E-luc), MMTV-LUC, and ARE-LUC were used (23, 93). The
NF-B-responsive reporter 3xRel-LUC (3), the AP-1-responsive promoter 3xAP-
1-LUC, and the (UAS)5-E1B-TATA-LUC reporter were as described previous-
ly (21). The wild-type human AR was subcloned from pARO into pcDNA3,
and the AR acetylation site mutants ARK630R, ARK630A, ARK(632/633)A, and
ARK(630/632/633)R were derived by PCR with sequence-specific primers and
cloned into pcDNA3. The integrity of all constructs was confirmed by se-
quence analysis. The expression vectors for Gal4-Sp1 (65), pCMVSRC1a
(38), TIP60 (35), ARA70 (92), ARA55, Ubc9 (68), Smad3, Smad3C (40),
pCEP4-MEKK1wt (67), pCMV-FlagN-CoR (6), pCMV-HDAC1 (13), and
pCMV-EGFP were previously described.
Cell culture, DNA transfection, and luciferase assays. Cell culture, DNA
transfection, and luciferase assays were performed as previously described (16,
21). The prostate cancer cell line DU145 and the HEK293 cell line were cultured
in Dulbecco’s minimal essential medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 1% penicillin, and 1% streptomycin. In studies of cellular
apoptosis with MEKK1, transfections were performed exactly as previously de-
scribed (2). Cells were plated at a density of 5  105 cells in a 60-mm-diameter
dish on the day prior to transfection. For DU145 cells, Lipofectamine Plus
(Gibco BRL) was used. The DNA-Lipofectamine mix was added to the cells in
optimem. Cells were incubated in media containing 10% charcoal-stripped fetal
bovine serum prior to experimentation with DHT (23). At least two different
plasmid preparations of each construct were used. In cotransfection experiments,
a dose response was determined in each experiment with 300 and 600 ng of
expression vector and the promoter reporter plasmids (2.4 g). Luciferase ac-
tivity was normalized for transfection with -galactosidase reporters as internal
controls. Luciferase assays were performed at room temperature with an Au-
tolumat LB 953 (EG&G Berthold) (88). The fold effect was determined for 300
to 600 ng of expression vector with comparison made to the effect of the empty
expression vector cassette, and statistical analyses were performed by using the
Mann-Whitney U test.
In vitro SUMO conjugation assays. SAE2/SAE1, Ubc9, and SUMO-1 were
expressed in Escherichia coli B834 and purified as described previously (82). In
vitro transcription-translation of proteins was performed by using 1 g of plas-
mid DNA and a wheat germ coupled transcription-translation system according
to the instructions provided by the manufacturer (Promega, Madison, Wis.).
[35S]methionine (Amersham) was used in the reactions to generate radiolabeled
proteins. SUMO conjugation assays were performed in 10-l volumes containing
1 l of [35S]methionine-labeled substrate (AR or promyelocytic leukemia [PML]
protein), 10 g of SUMO-1, 120 ng of SAE1/SAE2, and 650 ng of Ubc9 in 50
mM Tris (pH 7.5), 5 mM MgCl2, 2 mM ATP, and 10 mM creatine phosphate
(containing 3.5 U of creatine kinase/ml and 0.6 U of inorganic pyrophosphatase/
ml). The reaction mixtures were incubated at 37°C for 120 min. After termina-
tion with sodium dodecyl sulfate (SDS) sample buffer containing -mercapto-
ethanol, reaction products were fractionated by electrophoresis in 8%
polyacrylamide gels containing SDS, stained, destained, and dried before analysis
by phosphorimaging.
Protease sensitivity and ligand-binding assays. Protease sensitivity assays
were performed as previously described (10), with minor modifications. In vitro
[35S]methionine-labeled ARwt and ARK630A proteins were prepared by coupled
transcription-translation with a Promega TNT coupled reticulocyte lysate kit
(Promega) with 1.0 g of plasmid DNA in a total volume of 50 l. The translated
products were subsequently separated into 22.5-l aliquots and treated with or
without DHT (10 nM) for 20 min at 25°C. The mixtures were then separated into
4.5-l aliquots and incubated with increasing amounts of trypsin as indicated for
10 min at 25°C. The digestion was terminated by the addition of 20 l of
denaturing gel loading buffer and boiling for 5 min. The products of the digestion
were separated by SDS–12% polyacrylamide gel electrophoresis (PAGE) and
visualized by autoradiography.
Ligand-binding assays were performed as described previously (79) with equal
amounts of in vitro-translated recombinant wild-type AR and mutant ARs di-
luted to a total volume of 2 l in ligand-binding buffer (50 mM Tris, 1 mM
EDTA, 10% glycerol, 1 mM dithiothreitol [pH 7.5]). Fifty microliters of this
dilution was mixed with 50 l of different concentrations of [1,2,4,5,6,7-3H]DHT
(127 Ci/mmol) with or without a 200-fold excess of unlabeled DHT and incu-
bated at 4°C for 2 h. Unbound steroids were removed with HAP (79), and counts
per minute were determined by liquid scintillation counting.
Western blots, IP, and electrophoretic mobility shift assays (EMSAs). West-
ern and immunoprecipitation (IP)-Western blotting were performed as previ-
ously described (73). The antibodies used in Western blot analysis were rabbit
anti-AR antibody (N-20), the polyclonal p300 antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, Calif.) (4), anti-Flag antibody (M2; Sigma) (73), and anti-
HDAC1 antibody (Upstate Biotechnology, Lake Placid, N.Y.). The guanine
nucleotide dissociation inhibitor antibody (a generous gift from Perry Bickel,
Washington University, St. Louis, Mo.) was used as an internal control for
protein abundance (47). For the detection of protein, the membrane was incu-
bated with anti-AR (N-20) (1:1,000), anti-p300 (N-20) (1:1,000), anti-HDAC1,
and anti-M2 Flag antibody for Flag N-CoR at room temperature for 2 h or at 4°C
overnight. The blots were then washed three times with 0.5% Tween 20–phos-
phate-buffered saline and incubated with the appropriate horseradish peroxi-
dase-conjugated secondary antibody. The proteins were visualized by the en-
hanced chemiluminescence system (Amersham Pharmacia Biotech). The
abundance of immunoreactive protein was quantified by phosphorimaging with
an Image Quant, version 1.11, computing densitometer (Molecular Dynamics,
Sunnyvale, Calif.).
IP-Western blotting was performed as previously described (73) with the
lysates from HEK293 cells transfected with pcDNA3AR, pcDNA3ARK630A,
pcDNA3ARK(632/633)A, pCMVHA-p300, pCMV-FlagN-CoR, or an empty ex-
pression vector cassette as a control. The cells were treated for 24 h with 100 nM
DHT or vehicle. Cells were rinsed with phosphate-buffered saline, harvested by
scraping, pelleted, and lysed in buffer (50 mM HEPES [pH 7.2], 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 0.1% Tween 20, 0.1 mM
phenylmethylsulfonyl fluoride, 2.5 g of leupeptin/ml, 0.1 mM sodium or-
thovanadate [Sigma]). The extracts were cleared by centrifugation and further
precleared by rocking at 4°C with washed protein A-agarose beads (Roche
Molecular Biochemicals, Indianapolis, Ind.). The precleared extracts were im-
munoprecipitated with 0.5 g of AR antibody or equivalent amounts of the
appropriate control immunoglobulin G and 50 l of protein A-agarose for 8 to
12 h at 4°C. The beads were washed five times with lysis buffer and boiled in SDS
sample buffer, and the released proteins were resolved by SDS-PAGE. The gels
were transferred to nitrocellulose, and Western blotting was performed.
EMSAs were performed as previously described by using the ARE sequence
(74). Oligonucleotides encoding the high-affinity androgen response element
(74) (5	-ATG CAT TGG GTA CAT CTT GTT CAC ATA GAC A-3	) and its
complementary strand were used for EMSAs as recently described (8). In vitro
translation products of ARwt, ARK630A, and ARK630R were generated by using
the TNT T7/SP6 Coupled Reticulocyte Lysate system (Promega) and 1 g of
plasmid DNA for ARwt, ARK630A, and ARK630R. The level of the ARs synthe-
sized was assessed by Western blot analysis and shown to be similar. The binding
reaction was performed with 3 l of in vitro-translated AR, 100 fmol of
[
-32P]ATP-labeled probe, and 1.0 g of poly[d(I-C)] in 20 mM Tris (pH 7.9), 0.5
mM EDTA, 2.5 mM MgCl2, 1.5 mM dithiothreitol, 100 mg of Pefabloc SC/ml,
10% glycerin, 100 nM DHT, and 200 M ZnCl2. The reaction mixture was
incubated on ice for 30 min. The complexes were separated on 5% polyacryl-
amide gels in 0.5 Tris-borate-EDTA. The gels were vacuum dried at 80°C for
2 h, and the protein-DNA complexes were visualized by autoradiography.
Apoptosis assays. The thiazolyl blue (MTT) assay, which is a quantitative
colorimetric assay for mammalian cell survival and proliferation, was performed
as previously described (93). Briefly, 2  103 cells of the DU145 stable cell lines
for ARwt, ARK630A, and ARK(632/633)A were grown in 96-well plates in 50 l of
DMEM with 10% charcoal-stripped FBS. After 24 h, the cells were treated with
either vehicle or 10 nM DHT for approximately 20 to 30 min to engage the
endogenous AR (71) and then treated with either cycloheximide (10 g/ml),
TNF-related apoptosis-inducing ligand (TRAIL) (10 ng/ml) (R&D Systems,
Minneapolis, Minn.), TNF- (10 ng/ml) (Promega), or tetradecanoyl phorbol
acetate (TPA) (100 ng/ml). After 6 h, 20 l of MTT (5 mg/ml; Sigma) was added
to each plate for 3 h at 37°C. After incubation, 200 l of 0.04 N HCl in
isopropanol was added to each well. After several rounds of pipetting and 5 min
of incubation at room temperature, the absorbency was read at a test wavelength
of 490 nm. Comparisons were made within each cell line to the vehicle-treated
standard (control), as it could not be assumed that cellular division rates were
identical between the cell lines (78).
In separate experiments, the stable cell lines were treated as described above
and then analyzed directly for morphological features of apoptosis after direct
fixation of all cells with 10% paraformaldehyde. This procedure ensured fixation
of both adherent and nonadherent cells that had undergone apoptosis. At least
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three high-power fields chosen at random were assessed for each treatment to
ensure the counting of at least 300 cells. The percent apoptotic cells was scored
for blebbing and chromatin condensation. Data are shown as the relative change
in apoptosis by the inducing agent in the presence of 10 nM DHT.
In studies with MEKK1, apoptosis was detected by morphological analysis of
green fluorescent protein (GFP)-transfected cells (2). Equal amounts of GFP
were transfected into the wells with either the ARwt or the AR mutants; thus,
GFP itself was not an independent variable between the groups compared. At
least 200 cells were counted by using a fluorescent microscope, and cells were
scored for blebbing and chromatin condensation by an investigator blinded to the
experimental condition. At 24 h posttransfection, cells were treated with either
100 nM DHT or vehicle, and at 48 h, the cells were rinsed with phosphate-
buffered saline, fixed with 4% paraformaldehyde for 15 min, permeabilized with
0.5% Triton X-100, and stained for DNA with Hoechst 3325 dye (5 g/ml).
RESULTS
DHT-induced AR activity involves lysine residues acetylated
in vitro. In previous studies, the AR was shown to be acety-
lated in cultured cells with anti-acetyl lysine antibodies (23).
Either p300 or P/CAF was capable of acetylating the AR in
vitro, and Edman degradation analysis of the acetylated AR
products demonstrated that lysines 630, 632, and 633 were
preferentially acetylated, constituting an acetylation motif that
is conserved between species (Fig. 1A). Only monoacetylated
lysine-containing peptides were detected in the samples by
matrix-assisted laser desorption ionization–time of flight mass
spectrometry, indicating that the product analyzed by Edman
degradation was a heterogeneous population of peptides, each
acetylated at a single site. We assessed the role of the in vitro
AR acetylation sites in ligand sensitivity with point mutants of
the AR acetylation sites and reporter genes encoding a specific
ARE (ARE-LUC), an endogenous androgen-responsive gene
(PSA-LUC), or the androgen-responsive MMTV-LUC.
In the presence of DHT, ARE-LUC activity was induced six-
to sevenfold by the ARwt compared with the empty pcDNA3
vector but was induced less than 50% by either of the AR acet-
ylation site mutants (Fig. 1A). We next assessed the role for
the AR lysine residues in regulating basal and ligand-treated
AR function with the androgen-responsive PSA gene promot-
er linked to the luciferase reporter gene in the prostate cancer
cell line DU145 (Fig. 1B). The ARwt enhanced basal AR ac-
tivity 2.5-fold. The addition of DHT (106 M) induced AR
activity 4.3-fold. The expression plasmid encoding the AR acet-
ylation site mutant (ARK630A) increased basal AR activity 1.5-
fold compared with the empty expression vector cassette; how-
ever, there was no significant increase in DHT-induced activity
of the PSA-LUC reporter. Expression of the ARK(632/633)A
construction enhanced basal AR activity 1.7-fold; however,
DHT-induced activity was reduced 50 to 60% compared with
the wild type (Fig. 1B). To assess whether ligand sensitivity was
affected at subphysiological concentrations, dose-response
curves were examined. The androgen-responsive MMTV-LUC
reporter was induced threefold by ARwt compared with the
empty pcDNA3 vector with 1 to 10 nM DHT in DU145 cells;
however, the AR acetylation mutants were not induced (Fig.
1C).
Similar studies were performed with point mutants in which
the AR lysine residues were replaced with arginine (Fig. 1D
and E). In HEK cells, the MMTV-LUC reporter was induced
by ARwt four- to fivefold; however, the arginine substitution
mutants were not induced by DHT. Similar observations were
made in DU145 prostate cancer cells (Fig. 1E). In previous
studies of DU145 cells, it has been shown that the ligand-
treated AR does not induce either the pA3LUC vector or
several other luciferase reporter genes (RSV-LUC, cyclin E-
LUC, and c-Fos-LUC) (73), suggesting that the induction of
the PSA-LUC and MMTV-LUC reporters is promoter spe-
cific. The expression plasmids encoding point mutations of the
AR acetylation site were shown to be expressed in numbers
equal to those of the wild type in cultured cells (see Fig. 4G,
left panel). Together these studies suggest that the AR acety-
lation sites reduce both basal and ligand-induced activity of
androgen-responsive reporter genes.
The AR acetylation site does not regulate AR trans-repres-
sion function. The AR inhibits AP-1 activity in different cell
types, which likely involves several different mechanisms (39,
76, 77). The ability of the AR to inhibit AP-1 activity was
assessed by using the AP-1 site from the collagenase promoter.
The ARwt and the AR acetylation mutants inhibited AP-1
activity approximately 60 to 75% (Fig. 2A). In the presence of
DHT, ARwt repressed AP-1 activity by 80% and the AR mu-
tants repressed AP-1 activity by 70% (Fig. 2B). Several genes
downregulated by androgen contain NF-B binding sites, and
the AR attenuates NF-B reporter activity in a dose-depen-
dent manner (62). We assessed NF-B activity with the well-
characterized 3xRel-LUC reporter gene (3). The ARwt and
the AR mutants inhibited 3xRel-LUC reporter activity 50% in
the absence of ligand and 60 to 70% in the presence of DHT
(Fig. 2C and D). The AR forms a physical interaction with Sp1
and shares a common coactivator, SNURF (52, 69). The ability
of the ARwt to regulate Sp1 function was examined in DU145
cells with a heterologous reporter gene system. The Sp1 coding
region was linked to the Gal4 DNA binding domain, and ac-
tivity was assessed with a heterologous reporter consisting of
multimerized Gal4 DNA binding sites linked to the luciferase
reporter gene (UAS)5-E1B-TATA-LUC (Fig. 2E). The ARwt
repressed Sp1 activity 30 to 50%, and similar repression was
observed with the AR acetylation mutant (Fig. 2E and F).
Together these studies suggest that the ability of the AR to
trans repress the activity of several distinct signaling pathways
is not affected by the mutation of the AR acetylation site.
In vitro sumoylation and DNA binding of the AR are not
dependent upon the AR acetylation site. In order to investigate
the mechanisms responsible for the defect in ligand-dependent
transactivation of the AR acetylation site mutants, we exam-
ined the possibility that the acetylation site may regulate AR
sumoylation, AR gross structure in the presence of ligand, and
DNA binding. Acceptors of SUMO-1 modification are not
targeted for degradation, unlike the majority of ubiquitinated
proteins; however, the transcriptional activity of specific pro-
teins appears to be affected. The AR binds Ubc9 in a region
that includes the AR acetylation motif (68), and Ubc9 has the
capacity to serve as an E3 for sumoylation. The ligand-depen-
dent transactivation of the AR is regulated by sumoylation
(70); therefore, we investigated the possibility that the AR
acetylation site may play a role in the defective ligand-depen-
dent transactivation of the AR acetylation mutants. Modifica-
tion of the PML protein by sumoylation targets it to distinct
nuclear bodies (20), and 35S-labeled in vitro-translated PML
serves as an ideal substrate for in vitro sumoylation assays with
Ubc9 (82). As expected, PML was modified by SUMO-1 that
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FIG. 1. The AR acetylation site is required for DHT-mediated activation of androgen-responsive reporter genes. (A) Schematic representation
of the human AR indicating the DNA binding domain (DBD), the LBD, and the conserved KXKK motif (indicated by asterisks). The androgen-
responsive reporter gene ARE-LUC (A), PSA-LUC (B), or MMTV-LUC (C) was transfected into DU145 cells with either the ARwt or AR
acetylation site mutant expression plasmids. The cells were treated for 24 h with either vehicle, DHT (107 M), or DHT at concentrations ranging
from 0.1 to 10 nM (C) as indicated. Luciferase activity was determined, and the data are shown as means  standard deviations for at least six
separate transfections. The MMTV-LUC reporter was transfected into DU145 (D) or HEK293 (E) cells either alone or with the expression
plasmid encoding ARwt or the AR acetylation site mutant (arginine substitution) expression plasmids. The cells were treated with either vehicle
or DHT (0.01, 0.1, 1, 10, 100 nM) as indicated for 24 h, and luciferase activity was determined. RLU, relative luciferase units.
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FIG. 2. The trans-repression function of the AR acetylation site mutants is preserved. The expression vectors for either the wild-type or mutant
AR or equal amounts of the empty expression vector cassettes (pCMV) were cotransfected into HEK293 cells with the luciferase reporter genes
for AP-1 (3xAP-1-LUC) (A and B), NF-B activity (3xRel-LUC) (C and D), or the (UAS)5-E1B-TATA-LUC heterologous reporter (E and F),
and the chimeric transcription factor for Sp-1 was fused to the Gal4 DNA binding domain. The cells were treated with either DHT (107 M) or
vehicle (Veh) for 24 h, and luciferase activity was assessed. The data are shown as means  standard deviations. The DHT treatment (107 M)
was for 24 h.
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FIG. 3. AR in vitro sumoylation, protease cleavage pattern, and in vitro DNA binding are not affected by the AR acetylation site. (A) The in
vitro SUMO-1 conjugation assays were conducted as described previously (82) with in vitro-translated 35S-labeled PML, ARwt, or AR acetylation
mutants as indicated. The unconjugated proteins are indicated by arrows, and the SUMO-1-conjugated forms are indicated by asterisks.
(B) Protease sensitivity assays were conducted with ARwt or AR mutants by using increasing concentrations of trypsin and either vehicle or DHT
as indicated. The full-length in vitro-translated 35S-labeled AR and the major trypsin digestion products are shown. (C) Equal amounts of in
vitro-translated 35S-labeled AR (shown by autoradiography) were used in an EMSA with a 32P-labeled high-affinity ARE (74). The DNA-protein
complex of delayed migration is indicated by an arrow. , present; , absent.
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occurred at several sites (Fig. 3A). The ARwt was also sumoy-
lated, and there was no significant difference in the pattern or
proportion of sumoylation of the AR acetylation mutants (Fig.
3A).
It is known that the addition of DHT induces a conforma-
tional change in the AR and that ligand-induced conforma-
tional changes of NHR can be assessed by limited proteolytic
digestion (10). To determine whether the AR lysine substitu-
tion mutations altered conformation of the full-length AR
protein in the presence of ligand, limited proteolytic digestion
was performed comparing the ARwt and the ARK630A. Trypsin
addition induced a dose-dependent cleavage pattern, with a
specific pattern induced in the presence of ligand (Fig. 3B,
lanes 3 and 4 versus lanes 7 and 8). The proteolytic pattern of
the ARK630A mutant in the presence or absence of ligand was
similar to that of the ARwt (Fig. 3B, lanes 7 and 8 versus lanes
15 and 16). The induction of trypsin cleavage upon ligand
addition was consistent with the similar in vitro ligand-binding
properties of the ARwt and the AR mutant within the physi-
ological range of the ligand (for ARwt, kDa  0.84 nM; for
ARK630A, kDa  1.3 nM). In addition, the DNA binding prop-
erties of the AR mutants were assayed. As several different
cellular proteins have been proposed to regulate the DNA
binding properties of the AR, we performed EMSAs with an
ARE previously identified as a selective AR-binding site (74)
and compared binding by using equal amounts of in vitro-
translated full-length AR protein (Fig. 3C). A specific DNA-
protein complex formed in the presence of the ARwt (Fig. 3D)
that was competed by a specific cognate competitor (data not
shown) and which was of mobility and intensity similar to those
of the mutant ARs.
Mutation of the conserved AR lysine residue abrogates co-
activator-dependent induction. Several distinct coactivators
have been described which can enhance AR activity in either
the presence or the absence of ligand. To investigate the pos-
sibility that reduced ligand-dependent transactivation of the
AR acetylation mutants was due to a selective defect in acti-
vation of the AR by a previously described coactivator, tran-
sient expression studies were conducted in DU145 cells with
the androgen-responsive MMTV-LUC reporter gene. TIP60
encodes an AR-interactive protein with a domain homologous
to the HAT domain of p300 and conveys DNA-dependent
ATPase activity that plays a role in DNA repair (35). The
activity of the ARwt was augmented 4-fold by TIP60 in the
absence of ligand and 12-fold in the presence of ligand (Fig.
4A). The basal activity of the AR mutant ARK630A was induced
fourfold by TIP60; however, in the presence of ligand there
was no significant additional induction (Fig. 4A). SRC1 binds
the non-ligand-treated AR through AF-1 (12), recruits p300
(91), and is known to augment ligand-treated AR function in
fibroblasts (12). Coexpression of SRC1 (38) increased the ac-
tivity of the ligand-treated ARwt sixfold, whereas the ARK630A
was not induced (Fig. 4B). The AR-binding proteins, ARA55
and ARA70, induced AR activity in some but not all studies
(12, 92). In the present studies, neither ARA55 nor ARA70
induced either the ARwt or the AR mutants (Fig. 4C and D).
The ARK(632/633)A mutant was also defective in ligand-induced
activation by each of the coactivators (data not shown). We
examined Ubc9, a homologue of the class E2 ubiquitin-conju-
gating enzymes, which is thought to function as an AR trans-
activator independently of its ubiquitin conjugation function
(68). The AR 629 to 633 region was necessary for Ubc9-in-
duced AR activity. Ubc9 augmented ligand-dependent activa-
tion of the ARwt three- to fourfold, whereas activity of
ARK630A was not enhanced by coexpression of Ubc9 (Fig. 4E).
Consistent with CBP induction of the AR in CV1 cells (1),
coexpression of p300 increased DHT-induced activity three- to
fourfold (Fig. 4F). In contrast, the ARK630A mutant was not
significantly induced by p300 in the presence of ligand (Fig.
4F). Together, these studies suggest that the AR acetylation
mutants are defective in transactivation by several distinct AR
coactivators.
Several models have been proposed to explain the mecha-
nisms by which p300 augments NR activity. p300 may augment
ligand-treated AR activity either by bridging AF-1 and AF-2
(34) or by interacting with the AR N terminus and the LBD
(22). Alternatively, p300 may, upon recruitment through SRC
coactivators (83, 85), facilitate histone acetylation and basal
machinery interactions to promote gene expression. To deter-
mine whether failed activation of the ARK630A by p300 was due
to reduced binding in cultured cells, IP-Western blotting was
performed. The ARwt and the AR mutants were transfected
into AR-deficient HEK293 cells with the p300 expression vec-
tor. The ARwt and the mutants showed similar levels of ex-
pression by Western blotting, and p300 levels were also similar
(Fig. 4G, left panel). IP showed equal amounts of the AR in
the immunoprecipitate (Fig. 4G, right panel). The amount of
p300 associated with AR was reduced in the ARK630A and
ARK(632/633)A mutants compared with ARwt (Fig. 4G, lane 4
versus lanes 5 and 6).
TSA induction and DHT-induced AR activity involve lysine
residues acetylated in vitro. In previous studies, the androgen-
responsive synthetic reporter gene MMTV-LUC was shown to
be induced in the presence of ARwt by the specific HDAC
inhibitor trichostatin A (TSA) (23, 53). We therefore assessed
the role of the in vitro AR acetylation sites on TSA sensitivity
with point mutants of the AR acetylation sites and the andro-
gen-responsive reporter gene MMTV-LUC in the human pros-
tate cancer cell line DU145. Increasing concentrations of TSA
induced the ARwt 2.5 to 3-fold at 10 to 20 nM compared with
the empty vector (pcDNA3) (Fig. 5A). In contrast, neither of
the AR acetylation site mutants, ARK630A and ARK(632/633)A,
was induced by TSA. TSA failed to augment ligand-treated AR
activity (23), suggesting that the mechanisms governing ligand-
treated activity and TSA sensitivity involve a common pathway.
As TSA is a specific inhibitor of HDACs, we investigated the
possibility that HDAC1 may physically associate with the AR
in vivo. Cellular extracts from the murine liver, which expresses
the AR (73), were immunoprecipitated with an AR-specific
antibody (73). Western blotting of the AR with an HDAC1-
specific antibody demonstrated the presence of HDAC1 in the
AR IP (Fig. 5B). The addition of DHT (107 M) reduced the
abundance of HDAC1 in the AR IP (Fig. 5C, lane 1 versus
lane 2). TSA treatment also reduced the amount of HDAC1
coprecipitated with the AR (Fig. 5C, lane 1 versus lane 3). The
addition of TSA to DHT did not significantly alter the amount
of HDAC1 bound to the AR (Fig. 5C, lane 3 versus lane 4).
The treatment with DHT and TSA did not affect the abun-
dance of HDAC1 in the cells (Fig. 5C, lane 6 versus lanes 7 and
8). Thus, HDAC1 coprecipitates with the AR in vivo and in
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FIG. 4. The AR acetylation site regulates coactivator-mediated induction of ligand-treated AR. The MMTV-LUC reporter was cotransfected
with expression vectors for either the wild-type or mutant AR and the candidate AR coactivators TIP60 (A), SRC1 (B), ARA55 (C), ARA70 (D),
Ubc9 (E), and p300 (F) or equal amounts of the empty expression vector cassettes (pCMV). The cells were treated with either DHT (107 M)
or vehicle for 24 h, and luciferase activity was assessed. The data are shown as the means  standard deviations for at least six separate
transfections. DHT treatment (107 M) was for 24 h. (G) The ARwt and AR acetylation site mutant were transfected into HEK293 cells, and
Western blotting was performed for AR, p300, and the loading control guanine nucleotide dissociation inhibitor (GDI). In the right panel, equal
amounts of the cellular extracts were immunoprecipitated with the AR antibody, and Western blotting was performed with either the AR or the
p300 antibody. , present; , absent.
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cultured cells and the association between HDAC1 and the
AR is regulated by DHT or TSA.
Increased N-CoR binding of the AR acetylation mutant.
HDAC1 is found in a large transcriptional regulatory complex
that includes the corepressors mSIN3 and N-CoR (6, 30, 59).
In recent studies, N-CoR was shown to bind Smad3 (reviewed
in reference 43) and Smad3 was shown to inhibit ligand-in-
duced AR activity in CV1 cells (29). We therefore investigated
the possibility that Smad3 may repress ligand-induced AR
activity in prostate cancer cells. Cotransfection of the AR
with Smad3 showed that the ligand-treated AR activity was
repressed 70% by Smad3 (Fig. 6A). The carboxyl terminus
of Smad3 was required for protein-protein interaction with
the AR (29). The C-terminal deletion mutant of Smad3
FIG. 5. TSA induction of the AR involves the AR acetylation site. (A) The expression plasmids encoding the wild-type and mutant AR were
transfected into DU145 cells with the MMTV-LUC reporter. The cells were treated with either vehicle or TSA at the dose indicated for 24 h, and
luciferase activity was determined. The data are means  standard errors of the means for at least six separate transfections. (B) IP was performed
with murine hepatic extracts with an AR-specific antibody, with sequential Western blotting for either AR or HDAC1. (C) Hepatocellular extracts
were treated with either vehicle, TSA (30 nM), or DHT (100 nM) and subjected to IP with an AR-specific antibody. The AR IP was
electrophoresed on an SDS-PAGE gel, and Western blotting was performed for AR or HDAC1 (lanes 1 to 4). In the right panel (lanes 5 to 9),
the supernatant was analyzed by Western blotting. The absence of AR in the IP supernatant indicates that the IP is saturating. Similar levels of
HDAC1 are seen in the supernatant treated with vehicle, TSA, or DHT. , present; GDI, guanine nucleotide dissociation inhibitor.
FIG. 6. Enhanced N-CoR binding of the AR acetylation site mutant in cultured cells. (A) Smad3 binds components of the HDAC regulatory
complex (HDAC1, N-CoR). Smad3 or a Smad3 mutant with the carboxyl terminus deleted (Smad3C) was transfected with the MMTV-LUC
reporter into DU145 cells with either ARwt or the AR acetylation site mutant, and the cells were treated with DHT for 24 h. (B) The binding of
N-CoR to the AR was determined by IP-Western blotting. HEK293 cells transfected with expression vectors for FlagN-CoR and either ARwt or
the AR acetylation site mutant were assessed by Western blotting in the presence of DHT for expression levels. Similar levels of AR are shown
by Western blotting. Equal amounts of cell extracts were subjected to IP with anti-Flag antibody (M2) to precipitate N-CoR and Western blotting
performed for Flag (N-CoR) and the AR. AR immunoreactivity is detected in the N-CoR IP. , present; , absent; GDI, guanine nucleotide
dissociation inhibitor.
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(Smad3C) failed to repress the activity of the ligand-treated
AR. Smad3 had no effect on the activity of either ARK630A or
ARK(632/633)A (Fig. 6A). Smad3 repression is thought to be
mediated through N-CoR/HDAC1. As Smad3 repressed ARwt
to the level of activity seen for ARK630A or ARK(632/633)A, we
considered the possibility that the reduced activity of the li-
gand-treated AR acetylation mutants may be a function of
their enhanced binding to corepressors of the Smad3/N-CoR
complex. As Smad3 repression is thought to involve N-CoR
binding (29, 43), we examined the interaction between N-CoR
and the AR. IP-Western blotting was performed with HEK293
cells transfected with equal amounts of Flag-tagged N-CoR
and AR. Western blotting showed that similar levels of N-CoR
were expressed in transfected cells and that the expression
levels of the ARwt and AR mutant were similar (Fig. 6B, lanes
2 and 3). IP with the anti-Flag antibody showed similar
amounts of N-CoR by IP (Fig. 6B, lanes 4 to 6). The amount
of N-CoR bound to ARK630A was 10-fold higher than that with
the ARwt in the presence of DHT (Fig. 6B, right panel, lane 5
versus lane 6).
The AR acetylation site regulates AR function induced by
JNK in prostate cancer cells. It is known that the AR can
induce cell cycle arrest or apoptosis when introduced into
AR-negative cells and that overexpression of the AR in trans-
genic animals is associated with increased cellular apoptosis
(11, 80). TRAIL and TNF- in the presence of cycloheximide
induce prostate cancer cellular apoptosis (7, 58, 60, 94). To
further investigate the functional properties of the AR acety-
lation site, stable prostate cancer cell lines (DU145) expressing
either ARwt, AR acetylation site mutant, or control vector
pcDNA3 were made and examined for responses to cellular
apoptosis-inducing agents. Analyses were performed with at
least three separate experimental analyses of each line, and the
findings were representative of at least three separate stable
lines. Initial experiments were conducted with the MTT assay.
The cells were treated with either vehicle or DHT (100 nM) for
approximately 30 min to engage the AR with ligand (71), and
then the cells were treated with apoptosis-inducing agents.
Treatment of the ARwt DU145 cells with TRAIL (50 ng/ml) in
the presence of cycloheximide (2 M) inhibited MTT activity
55% compared with vehicle, and either TNF- or TPA inhib-
ited activity by 40 to 50% (Fig. 7A). In contrast, the AR
acetylation mutant stable lines showed no change in activity
with any of these treatments (Fig. 7A) (n  6, P  0.01).
Direct measurement of morphological features of apoptosis
was also performed, as both cellular proliferation and apopto-
sis may affect activity in the MTT assay. Cells may become
detached upon apoptosis and may become underrepresented
in analysis; therefore, cells were fixed in a manner to include
both adherent and nonadherent cells and scored for apoptosis
by morphological features in separate experiments (48, 78).
The cells were pretreated with vehicle or 100 nM DHT for 30
min and then treated with apoptosis-inducing agent for 6 h
(Fig. 7B and C). At least 300 cells were scored in three inde-
pendent high-power fields as described in Materials and Meth-
ods. The relative apoptosis rate of the ARwt-expressing stable
DU145 cells was increased by either TRAIL or TRAIL with
cycloheximide in the presence of ligand compared with the
vehicle control. In contrast, the stable DU145 cell line express-
ing the AR acetylation mutants did not show the same induc-
tion of apoptosis in the presence of DHT (Fig. 7B and C).
Transient expression studies were also conducted to exam-
ine the role of the AR acetylation site in AR mutant proteins.
To assess the role of the AR acetylation site in AR-mediated
apoptosis, a previously described experimental approach was
used (2). AR activity is induced by the MAPK kinase kinase,
MEKK1, which induces phosphorylation of MKK4 (SEK1)
and JNK as well as IB kinase (37, 46). Activation of MEKK1
induces apoptosis of prostate cancer cells in an AR-dependent
manner through the JNK pathway (2). To examine the func-
tional significance of the AR acetylation site in MEKK1-in-
duced prostate cellular apoptosis, studies were performed in
DU145 cells exactly as previously described (2). Cells were
cotransfected with either wild-type or mutant ARs and either
the MEKK1 expression vector or control empty vector. A GFP
expression vector was used to monitor the transfected cells.
The cells were treated for 24 h with either DHT (107 M) or
control vehicle and scored for apoptosis with morphological
markers of blebbing or nuclear condensation (Fig. 7D). The
expression of either the ARwt or MEKK1 alone did not affect
basal apoptosis compared with equal amounts of empty vector
cassette (Fig. 7E). In contrast, the coexpression of MEKK1
and the ARwt in the presence of ligand induced apoptosis to
approximately 30% as previously described (2). Coexpression
of MEKK1 with either ARK630A or ARK(632/633)A resulted in
an apoptosis rate similar to that of vector controls (Fig. 7E).
These studies demonstrate an important function of the AR
acetylation site in regulating MEKK1-dependent apoptosis in
cultured human prostate cancer cells.
DISCUSSION
The recent findings that nonhistone proteins serve as direct
targets of histone acetylases have led to further mechanistic
analysis of the substrate residues in transcription factor func-
tion (81, 86). The AR conveys both trans-repression and trans-
activation function. In the present studies, the AR acetylation
site selectively regulated the AR trans activation but not the
trans-repression functions. The sumoylation of the AR was
unaffected by the mutation of the AR acetylation site in vitro.
Ligand-induced conformational changes, assessed by limited
protease digestion, showed a similar pattern induced by the
ligand in the ARwt and the AR acetylation mutant. Intrigu-
ingly, the AR acetylation mutants showed increased N-CoR
binding and reduced p300 binding compared with the wild-type
AR. As p300 and N-CoR regulate ligand-dependent gene ex-
pression of other NHR, these studies suggest that the AR
lysine residues may play an important role in a subset of AR
functions by regulating recruitment of hormone-dependent co-
regulators.
The role of direct transcription factor acetylation in hor-
mone signaling to endogenous androgen-regulated target
genes was largely unknown. In the present studies, point mu-
tation of the AR lysine residues, which was previously shown to
abrogate acetylation of the full-length AR protein (23), sub-
stantially reduced DHT-dependent activation of several andro-
gen-responsive reporters, including the PSA promoter, the
MMTV promoter, and a simple synthetic androgen response
element. PSA, an endogenous androgen-regulated target gene,
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FIG. 7. Induction of apoptosis and the AR acetylation site. (A) Induction of apoptosis by TRAIL is reduced in stable cell lines expressing the
AR acetylation site mutants. DU145 cells stably expressing either ARwt, ARK630A, or ARK(632/633)A were grown in 96-well plates in 50 l of DMEM
with 10% charcoal-stripped FBS. After 24 h, the cells were treated with vehicle or 100 nM DHT and then treated with either cycloheximide (CHX;
10 g/ml), TRAIL (10 ng/ml), TNF- (10 ng/ml), or TPA (100 ng/ml) as indicated. The MTT assay was performed after 6 h. The data are shown
as means  standard deviations for six separate experiments. Vehicle-treated cells are established as 100%. (B and C) DU145 stable lines were
treated with vehicle or 100 nM DHT for 30 min, and then apoptosis-inducing agents were added as indicated, and apoptotic cells were scored (see
Materials and Methods). Data are shown as the relative change in apoptosis by the inducing agent in the presence of 100 nM DHT. A
representative experiment is shown. (D) Induction of apoptosis by Jun kinase kinase (MEKK1) through the AR is abrogated by the mutation of
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is a prostate-specific kallikrein, the expression of which is used
to monitor patients with prostate cancer (24). The PSA pro-
moter has been well characterized as an androgen-responsive
gene. In the present studies, mutation of the AR acetylation
site reduced the transcriptional activity of androgen-responsive
reporter gene coactivation by several AR regulators (Ubc9,
SRC1, TIP60). Ubc9 trans activation of the AR occurs inde-
pendently of its ubiquitin-ligase function. The failure of Ubc9
to induce ARK630A activity is consistent with previous findings
that the AR hinge region, which includes the lysine motif, is
required for Ubc9 binding and activation (68). The interaction
of SRC1 with the AR involves the glutamine-rich region of
SRC1 and the AF-2 region of the AR. Coactivation of AR by
SRC1 requires AD1 of SRC1, the same region responsible for
recruitment of p300/CBP, and does not require the LXXLL
motif that interacts with AF-2 (12). Thus, failed SRC1 coacti-
vation of the acetylation site mutants is consistent with defec-
tive p300 coactivation. TIP60 binds the AR through a region
which includes the acetylation site (15), conveys intrinsic HAT
activity (15, 90), and regulates DNA repair and apoptosis (35).
As TIP60 augmented the activity of the ligand-treated ARwt
but not the AR mutant and MEKK1 augmented AR apoptosis
in the presence of ligand, it will be of interest to further eval-
uate the role of TIP60 in AR-mediated apoptosis.
What common features shared by this subset of coactivators
(SRC1, Ubc9, TIP60, and p300) might explain their reduced
ligand-dependent coactivation of the AR acetylation site mu-
tants? The bromodomains of several coactivators serve as rec-
ognition motifs providing recruitment to acetylated lysine res-
idues (36), and it is feasible that one or more of the
bromodomain-containing coactivators (p300, P/CAF) serves as
a docking module through the AR-acetylated residues for se-
quential recruitment of other coactivators. P/CAF, which
failed to activate the acetylation site mutants (23), is an im-
portant regulator of AR function in prostate cancer cells.
P/CAF binds the AR in vivo (73), binds p300, and contains a
bromodomain that is required for AR binding. p300 is viewed
as a limiting coactivator for many NR, including the AR; there-
fore, although the reduction in p300 binding to the AR mu-
tants was modest, reduced recruitment of coactivators may
contribute to the defective trans activation of the AR acetyla-
tion mutants.
Transcriptional repression by N-CoR involves a multipro-
tein complex that includes HDAC complexes, chromatin re-
modeling proteins, and a transducin -like protein that inter-
acts with histones (41, 59). In the present studies, the nuclear
corepressor N-CoR showed proportionally more binding to the
AR lysine point mutants in cultured DU145 cells. The en-
hanced N-CoR binding to the AR lysine point mutants may
provide an important mechanistic link to the reduced activity
of the AR acetylation-defective mutants. The finding that co-
activator and corepressor surfaces of NR overlap substantially
(32, 66) is compatible with a dynamic model in which enzy-
matic modifications of the NR coordinate the sequential dis-
engagement of corepressors followed by coactivator binding
(56). Enhanced corepressor binding of the AR acetylation-
defective mutants suggests a role for acetylation in the disen-
gagement of corepressors. Acetylation of upstream binding
factor also correlates with reduced transcriptional repression
by the pRB-recruited HDAC (64). Together these studies pro-
vide evidence for a model in which acetylation disengages
corepressors to sequentially recruit coactivators (45).
Several observations in the present studies suggest that the
defective transactivation of the AR acetylation mutants may
relate to altered coactivator-corepressor binding and does not
result from reduced expression levels or ligand binding. Firstly,
expression levels of the ARwt and the ARK630A or ARK(632/
633)A mutant proteins were similar in cultured cells, suggesting
that reduced transactivation was not due to reduced expres-
sion. The AR acetylation site does not fall within the ligand-
binding pocket deduced from the crystal structure (55), the AR
acetylation site mutants demonstrated wild-type ligand-in-
duced protease sensitivity, and in vitro ligand-binding assays
showed normal ligand-binding affinity at the physiological con-
centrations of ligand. Thus, the reduced ligand-induced trans-
activation of the AR acetylation mutants does not appear to be
due to reduced expression or altered ligand binding. The re-
cruitment of HDAC1/N-CoR-containing complexes to the pro-
moters of target genes induces a repressive chromatin state
through the functions of HDAC1 (19, 50). It has been pro-
posed that ligand-dependent activation of NHR involves both
recruitment of coactivators and disengagement of corepressors
(27). The present studies of the AR are consistent with a model
in which the selective defects in coactivation of the AR acet-
ylation mutants may be due to increased binding of N-CoR
regulated through the acetylation site.
The cellular phenotype regulated by direct acetylation of
specific transcription factor events remains to be determined.
Several studies have implicated direct transcription factor acet-
ylation in regulating reporter gene expression (81, 87). Thus,
acetylation regulates the transcriptional activity of p53 (28, 75),
GATA-1 (14), erythroid Kruppel-like factor (95), Xenopus
NF-Y (49), and the human immunodeficiency virus transacti-
vator protein (Tat) (42) in reporter assays. Only recently has
the functional cellular phenotype governed by transcription
factor acetylation been examined (63). Acetylation site muta-
tions of p53 were defective in repression of Ras-induced trans-
formation, suggesting an important functional role for p53
acetylation in vivo (63). In previous studies, the AR KXKK
motif was both necessary and sufficient for acetylation by either
p300 or P/CAF (23). This motif resembles the C-terminal p53
acetylation motif and is highly conserved between NHR, sug-
gesting an important biological function (86). Activation of the
MEKK1 pathway enhances AR activity and induces cellular
the AR acetylation site. DU145 cells were transfected with expression vectors for the AR, MEKK1, and pCMV-GFP or equal amounts of empty
vector control. The cells were treated for 24 h with DHT and scored for apoptosis 48 h posttransfection as previously described (2). The
morphology of the transfected DU145 cells is shown, in phase contrast. White arrows indicate GFP-positive cells, and the yellow arrows indicate
GFP-positive cells with chromatin condensation. (E) The graph represents independent experiments in which 200 green fluorescent cells were
counted and scored for cytoplasmic blebbing and chromatin condensation. The results are representative of three separate experiments., present;
, absent; DMSO, dimethyl sulfoxide.
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apoptosis in prostate cancer cells (2). In the present studies,
AR acetylation was a critical determinant of the apoptotic
response induced by MEKK1 in prostate cancer cells. Further-
more, stable cell lines expressing the AR acetylation mutants
showed no enhancement of apoptosis by several agents in the
presence of the ligand DHT. AR-dependent apoptosis has
been observed in cultured cells and in transgenic mice in which
the AR was targeted to the prostate by the probasin promoter
(80). Several agents can induce apoptosis through AR-depen-
dent and AR-independent pathways. Ligand-dependent events
correlate with AR-mediated nuclear events, as the AR is
thought to be required for nuclear DHT function. Therefore,
in the present studies, comparison was made between the ve-
hicle and the ligand to examine those apoptotic events most
likely regulated by the AR in the stable cell lines. It remains
possible, although unlikely, that DHT may govern non-AR-
dependent apoptotic events that were selectively altered by the
AR acetylation site, for example, through altered expression of
a paracrine growth factor. The mechanisms by which the AR
acetylation site regulates cellular apoptosis remain to be fur-
ther explored. The evasion of cellular apoptosis contributes to
aberrant growth control during tumorigenesis in multiple set-
tings. The identification of acetylation as a key posttransla-
tional modification required for activation of the AR by mul-
tiple distinct coactivators suggests that these residues may form
an ideal target for AR inactivation and tumor therapies.
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